CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating activities:
Net income (loss)	$ 481,447	$ (456,808)
Adjustments to reconcile net loss to net cash provided from operating activities:
Deferred income tax expense (benefit)	119,180	(120,832)
Depletion, depreciation and amortization and impairment of proved properties	86,562	85,604
Abandonment and impairment of unproved properties	7,510	1,996
Derivative fair value (income) loss	(367,967)	939,057
Cash settlements on derivative financial instruments	34,468	(133,135)
Divestiture contract obligation, including accretion, net of gain	12,215	10,954
Amortization of deferred financing costs and other	1,310	1,965
Deferred and stock-based compensation	20,681	86,113
Gain on the sale of assets	(138)	(331)
Loss on early extinguishment of debt	0	69,210
Changes in working capital:
Accounts receivable	225,213	58,674
Other current assets	(5,335)	(5,908)
Accounts payable	(10,822)	51,996
Accrued liabilities and other	(129,368)	(182,141)
Net cash provided from operating activities	474,956	406,414
Investing activities:
Additions to natural gas properties	(125,468)	(90,104)
Additions to field service assets	(74)	(37)
Acreage purchases	(12,742)	(12,599)
Proceeds from disposal of assets	660	349
Purchases of marketable securities held by the deferred compensation plan	(1,869)	(8,996)
Proceeds from the sales of marketable securities held by the deferred compensation plan	1,200	6,375
Net cash used in investing activities	(138,293)	(105,012)
Financing activities:
Borrowings on credit facilities	185,000	282,000
Repayments on credit facilities	(204,000)	(282,000)
Issuance of senior notes	0	500,000
Repayment of senior notes	0	(850,000)
Dividends paid	(19,334)	0
Treasury stock purchases	(7,834)	(16,199)
Debt issuance costs	0	(6,817)
Taxes paid for shares withheld	(39,057)	(24,995)
Change in cash overdrafts	(29,064)	(8,540)
Proceeds from the sales of common stock held by the deferred compensation plan	5,052	3,658
Net cash used in financing activities	(109,237)	(402,893)
Increase (decrease) in cash and cash equivalents	227,426	(101,491)
Cash and cash equivalents at beginning of period	207	214,422
Cash and cash equivalents at end of period	$ 227,633	$ 112,931